Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 104Colorectal Neoplasms 63Stomach Neoplasms 49Rectal Neoplasms 42Colonic Neoplasms 24Neoplasm Metastasis 21Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Pancreatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 12Neoplasms 12Gallbladder Neoplasms 7Cholangiocarcinoma 7Adenocarcinoma 6Esophageal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Esophageal Squamous Cell Carcinoma 4Neuroendocrine Tumors 3Gastrointestinal Neoplasms 3Digestive System Neoplasms 3Bile Duct Neoplasms 3Recurrence 2Pathologic Complete Response 2Liver Neoplasms 2Intestinal Neoplasms 2Hand-Foot Syndrome 2HER2-positive Advanced Breast Cancer 2HER2 Positive Metastatic Breast Cancer 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

Capecitabine 2Vinorelbine 1Trastuzumab 1Lapatinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × HER2-positive Advanced Breast Cancer × Capecitabine × Clear all
NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
420 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Bio-Thera Solutions

Phase 3 Unknown
410 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡